The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 330:1160-1161 April 21, 1994 Number 16
NextNext

Acute Vanishing Bile Duct Syndrome after Interferon Therapy for Recurrent HCV Infection in Liver-Transplant Recipients

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
To the Editor: Interferon alfa therapy has been recently proposed1 to treat patients with recurrent hepatitis C virus (HCV) infection following liver transplantation2,3. We report on two patients in whom we believe that interferon alfa therapy (interferon alfa-2b, Schering-Plough) may have triggered acute vanishing bile duct syndrome. Among 28 patients who received liver transplants for cirrhosis due to HCV between 1987 and 1992, serologic (enzyme-linked immunosorbent and recombinant immunoblotting assays), viral (polymerase chain reaction), and histologic evidence of recurrent HCV infection was demonstrated in 21. Interferon alfa therapy (3 million units three times weekly) was instituted in five patients . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.